TEMPORAL RESPONSE PATTERNS OF ABROCITINIB AND DUPILUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A POST HOC ANALYSIS OF THE JADE DARE TRIAL

被引：0
|
作者：
Trzeciak, Magdalena [1 ]
Chovatiya, Raj [2 ]
Geng, Bob [3 ]
Biswas, Pinaki [4 ]
Guler, Erman [5 ]
机构：
[1] Med Univ Gdansk, Dept Dermatol Venereol & Allergol, Gdansk, Poland
[2] Northwestern Univ, Dept Dermatol, Feinberg Sch Med, Chicago, IL USA
[3] Univ Calif San Diego, Dept Dermatol, Sch Med, San Diego, CA USA
[4] Pfizer Inc, New York, NY USA
[5] Pfizer Inc, Istanbul, Turkiye
来源：
ACTA DERMATO-VENEREOLOGICA | 2023年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P4.6
引用
收藏
页码：30 / 31
页数：2
相关论文
共 50 条
  • [31] Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Ferrucci, Silvia
    Casazza, Giovanni
    Zussino, Martina
    Tavecchio, Simona
    Marzano, Angelo V.
    Tedeschi, Micol
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
  • [32] Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis
    Frampton, James E.
    Blair, Hannah A.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (04) : 617 - 624
  • [33] Effect of abrocitinib vs dupilumab and placebo on patient-reported outcomes (PROs) in moderate-to-severe atopic dermatitis (AD) in JADE COMPARE
    Yosipovitch, Gil
    Thyssen, Jacob P.
    Paul, Carle
    Kwatra, Shawn G.
    Chu, Chia-Yu
    Rojo, Ricardo
    Valdez, Hernan
    Feeney, Claire
    Zhang, Fan
    Myers, Daniela E.
    DiBonaventura, Marco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB133 - AB133
  • [34] Long-term efficacy of abrocitinib up to 96 weeks in adults with moderate-to-severe atopic dermatitis stratified by age: a post hoc analysis of the JADE EXTEND phase 3 trial
    Alexis, Andrew F.
    Deleuran, Mette
    Silverberg, Jonathan, I
    Gooderham, Melinda J.
    Farooqui, Saleem A.
    Chan, Gary
    Koppensteiner, Herwig
    Biswas, Pinaki
    Watkins, Melissa
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [35] Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis
    Guttman-Yassky, Emma
    Facheris, Paola
    Gomez-Arias, Pedro Jesus
    Del Duca, Ester
    Da Rosa, Joel Correa
    Weidinger, Stephan
    Bissonnette, Robert
    Armstrong, April W.
    Seneschal, Julien
    Eyerich, Kilian
    Estrada, Yeriel D.
    Bose, Swaroop N.
    Xu, Dan
    Chen, Allshine
    Tatulych, Svitlana
    Guler, Erman
    Chan, Gary
    Page, Karen M.
    Kerkmann, Urs
    ALLERGY, 2024, 79 (05) : 1258 - 1270
  • [36] Abrocitinib in the Treatment of Moderate-to-Severe Atopic Dermatitis Refractory to Dupilumab Treatment: An Analysis of JADE-EXTEND, a Phase 3 Long Term Extension Study
    Shi, Vivian Y.
    Bhutani, Tina
    Deleuran, Mette
    Fonacier, Luz
    Shumack, Stephen
    Zhang, Fan
    Cameron, Michael C.
    Chan, Gary
    Valdez, Hernan
    Yin, Natalie
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 77 - 78
  • [37] Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
    Staender, Sonja
    Kwatra, Shawn G.
    Silverberg, Jonathan, I
    Simpson, Eric L.
    Thyssen, Jacob P.
    Yosipovitch, Gil
    Zhang, Fan
    Cameron, Michael C.
    Cella, Ricardo Rojo
    Valdez, Hernan
    DiBonaventura, Marco
    Feeney, Claire
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (01) : 97 - 107
  • [38] Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
    Sonja Ständer
    Shawn G. Kwatra
    Jonathan I. Silverberg
    Eric L. Simpson
    Jacob P. Thyssen
    Gil Yosipovitch
    Fan Zhang
    Michael C. Cameron
    Ricardo Rojo Cella
    Hernan Valdez
    Marco DiBonaventura
    Claire Feeney
    American Journal of Clinical Dermatology, 2023, 24 : 97 - 107
  • [39] Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis
    Mele-Ninot, Gemma
    Curto-Barredo, Laia
    Bonfill-Orti, Montserrat
    Exposito-Serrano, Vicente
    Munera-Campos, Monica
    Figueras Nart, Ignasi
    Riquelme-Mc Loughlin, Constanza
    Gomez-Armayones, Sara
    Spertino, Jorge
    Serra-Baldrich, Esther
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2024, 65 (02) : 153 - 162
  • [40] Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis
    Edwards, Steven J.
    Karner, Charlotta
    Jhita, Tracey
    Barton, Samantha
    Marceniuk, Gemma
    Yiu, Zenas Z. N.
    Wittmann, Miriam
    HEALTH TECHNOLOGY ASSESSMENT, 2024, 28 (04)
12345